In the past week, PTIX stock has gone up by 11.63%, with a monthly decline of -2.54% and a quarterly surge of 4.29%. The volatility ratio for the week is 8.26%, and the volatility levels for the last 30 days are 9.32% for Protagenic Therapeutics Inc. The simple moving average for the past 20 days is 6.33% for PTIX’s stock, with a -36.44% simple moving average for the past 200 days.
Is It Worth Investing in Protagenic Therapeutics Inc (NASDAQ: PTIX) Right Now?
There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of PTIX on June 26, 2025 was 2.06M shares.
PTIX) stock’s latest price update
Protagenic Therapeutics Inc (NASDAQ: PTIX)’s stock price has gone rise by 4.92 in comparison to its previous close of 3.66, however, the company has experienced a 11.63% increase in its stock price over the last five trading days. accessnewswire.com reported 2025-05-21 that NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the “Company”) announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company’s peptide-based drug candidates for stress-related and central-nervous-system disorders.
PTIX Trading at 1.97% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.29% of loss for the given period.
Stock Fundamentals for PTIX
The total capital return value is set at 61.25. Equity return is now at value -512.79, with -293.85 for asset returns.
Currently, EBITDA for the company is -5.47 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In summary, Protagenic Therapeutics Inc (PTIX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
